newsfilter
← Latest News
ClinicalTrials.gov·

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types - NCT05000294

Objective response rate (ORR), Progression free survival (PFS), Overall survival (OS), Disease control rate (DCR)